Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 2.400-2.500 for the period, compared to the consensus EPS estimate of 2.450. The company issued revenue guidance of $16.1 billion-$16.5 billion, compared to the consensus revenue estimate of $16.3 billion. Teva Pharmaceutical Industries also updated its FY24 guidance to $2.40-2.50 EPS.
Analysts Set New Price Targets
A number of equities analysts have commented on TEVA shares. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $19.67.
Read Our Latest Research Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.08 billion. Teva Pharmaceutical Industries had a positive return on equity of 41.43% and a negative net margin of 5.73%. Analysts forecast that Teva Pharmaceutical Industries will post 2.34 EPS for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- What is the Dogs of the Dow Strategy? Overview and Examples
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 11/4 – 11/8
- Most active stocks: Dollar volume vs share volume
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.